Eyepoint Pharmaceuticals (NASDAQ:EYPT) Earns Neutral Rating from HC Wainwright

Eyepoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports.

Several other brokerages also recently weighed in on EYPT. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Friday, July 17th. Jefferies Financial Group dropped their price target on Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating on the stock in a research note on Monday. Chardan Capital restated a “buy” rating and set a $65.00 price objective on shares of Eyepoint Pharmaceuticals in a report on Monday. Royal Bank Of Canada decreased their price objective on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $40.33.

Eyepoint Pharmaceuticals Stock Performance

NASDAQ:EYPT opened at $4.87 on Tuesday. Eyepoint Pharmaceuticals has a fifty-two week low of $3.95 and a fifty-two week high of $19.11. The stock has a market capitalization of $419.84 million, a P/E ratio of -1.30 and a beta of 1.76. The company’s 50-day simple moving average is $13.10 and its 200-day simple moving average is $13.62.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). The firm had revenue of $0.51 million during the quarter, compared to analysts’ expectations of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. On average, research analysts forecast that Eyepoint Pharmaceuticals will post -3.6 EPS for the current year.

Institutional Trading of Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EYPT. Stempoint Capital LP increased its holdings in shares of Eyepoint Pharmaceuticals by 129.1% in the first quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock valued at $10,451,000 after purchasing an additional 456,915 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Eyepoint Pharmaceuticals by 22.6% during the first quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after purchasing an additional 663,439 shares during the period. California State Teachers Retirement System lifted its holdings in shares of Eyepoint Pharmaceuticals by 2,158.3% during the first quarter. California State Teachers Retirement System now owns 105,101 shares of the company’s stock worth $1,355,000 after purchasing an additional 100,447 shares during the period. The Manufacturers Life Insurance Company boosted its position in Eyepoint Pharmaceuticals by 58.4% in the first quarter. The Manufacturers Life Insurance Company now owns 36,072 shares of the company’s stock valued at $465,000 after buying an additional 13,297 shares during the last quarter. Finally, Commodore Capital LP purchased a new stake in Eyepoint Pharmaceuticals in the first quarter valued at approximately $36,414,000. Institutional investors and hedge funds own 99.41% of the company’s stock.

Key Stories Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: EyePoint said DURAVYU was non-inferior to on-label aflibercept in an ad hoc analysis that excluded an asymmetric cohort of nine patients whose vision loss was considered unrelated to wet AMD. The trial also showed a 42% reduction in treatment burden, strong anatomic control through Week 56, supplement-free treatment rates and a favorable redosing safety profile. EyePoint Announces Topline Data from LUGANO
• Positive Sentiment: Jefferies lowered its price target to $8 but maintained a “buy” rating, while Chardan reaffirmed its “buy” rating and $65 target. These bullish views indicate some analysts believe the LUGANO result may be addressable and that DURAVYU’s longer-duration treatment profile retains value.
• Neutral Sentiment: Trading in EYPT was temporarily halted for pending news before the trial results were released, reflecting the material importance of the announcement. JPMorgan reaffirmed its “neutral” rating.
• Negative Sentiment: The full trial dataset did not meet the primary endpoint because the unusual vision-loss cohort affected the result. Investors now face greater regulatory and clinical uncertainty, particularly while awaiting the second pivotal Phase 3 trial. EyePoint’s eye drug misses main goal in late-stage trial
• Negative Sentiment: Cantor Fitzgerald downgraded EyePoint from “overweight” to “neutral.” The setback prompted speculation that competing ophthalmology companies, including Ocular Therapeutix and Forma Therapeutics, may now appear more attractive, further pressuring EYPT’s valuation.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.